Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Prelude Therapeutics (PRLD) EBITDA Margin (2024 - 2026)

Prelude Therapeutics' EBITDA Margin history spans 3 years, with the latest figure at 227.82% for Q1 2026.

  • On a quarterly basis, EBITDA Margin changed N/A to 227.82% in Q1 2026 year-over-year; TTM through Mar 2026 was 465.62%, a N/A change, with the full-year FY2025 number at 819.81%, up 99963.0% from a year prior.
  • EBITDA Margin hit 227.82% in Q1 2026 for Prelude Therapeutics, up from 291.68% in the prior quarter.
  • Over the last five years, EBITDA Margin for PRLD hit a ceiling of 227.82% in Q1 2026 and a floor of 1060.47% in Q3 2024.
  • Historically, EBITDA Margin has averaged 520.99% across 3 years, with a median of 303.42% in 2025.
  • The widest YoY moves for EBITDA Margin: up 75705bps in 2025, down 42989bps in 2025.
  • Tracing PRLD's EBITDA Margin over 3 years: stood at 721.58% in 2024, then soared by 60bps to 291.68% in 2025, then rose by 22bps to 227.82% in 2026.
  • Business Quant data shows EBITDA Margin for PRLD at 227.82% in Q1 2026, 291.68% in Q4 2025, and 303.42% in Q3 2025.